Special Bulletin

Updated: October 13, 2023
October 10, 2023

New COVID-19 Booster Vaccines Added to the Preventive Schedule

The Centers for Disease Control and Prevention (CDC) has recently approved new, single-dose COVID-19 booster vaccines from Pfizer, Moderna, and Novavax to protect against the XBB variant. The Pfizer and Moderna boosters are for all persons 6 months and older; the Novavax vaccine is for individuals 12 and older.

Member Cost Share

For members who have plans with the standard preventive schedule, *it is likely that there will be no member cost share.* However, it is possible that some members may see **out-of-pocket costs** when receiving the new vaccine if their group health plan does not cover this preventive benefit.

For benefits to be paid, the member must be eligible on the date of service and the service must be a covered benefit. Providers should use the provider portal — Availity® or NaviNet® — or the applicable HIPAA electronic transactions to check member benefits.

Members may incur out-of-pocket costs if they receive vaccines from a non-network provider.* COVID-19 vaccinations, including boosters, are covered for members with **Medicare Part B.** For cost-share questions regarding COVID-19 boosters, members can call the number on the back of their Highmark member card.

Table 1: New Pfizer Vaccine Product Codes and Age Ranges

Procedure Code	Descriptor	Age Range
91318	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 3 mcg/0.2 mL dosage, tris-sucrose formulation, for intramuscular use	6 months through 4 years
91319	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 10 mcg/0.2 mL dosage, tris-sucrose formulation, for intramuscular use	5 years through 11 years
91320	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 10 mcg/0.2 mL dosage, tris-sucrose formulation, for intramuscular use	12 years and older

Table 2: New Moderna Vaccine Product Codes and Age Ranges

Procedure Code	Descriptor	Age Range
91321	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 25 mcg/0.25 mL dosage, for intramuscular use	6 months through 11 years
91322	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 50 mcg/0.5 mL dosage, for intramuscular use	12 years and older

Table 3: New Novavax Vaccine Product Code and Age Ranges

Procedure Code	Descriptor	Age Range
91304	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5mL dosage, for intramuscular use	12 years and older

Note: The newly approved updated Novavax vaccine — which went into effect on October 1, 2023 — is using the same procedure code as the original Novavax vaccine. The Pfizer and Moderna booster vaccines went in effect on September 11, 2023.

Vaccine Administration Code

For the administration of these new booster vaccines (91304, 91318 – 91322), providers should use the following administration code: **90480**.

Updated Immunization Schedules

To view the updated **2023 Immunization Schedules**, go to the Provider Resource Center. Select **EDUCATION/MANUALS** from the left menu and the click **Preventive Health Guidelines**. Once you arrive at the page, scroll down to the **2023 Immunization Schedules** section, which includes links to the CDC-approved immunization schedules for children and adults:

- Children Ages 0-18 Immunization Schedule
- Adult Ages 19 and Older Immunization Schedule

Reference

There is no out-of-network coverage for Medicare Advantage HMO plans excluding HMO-Point of Service (POS) plans.

HIGHMARK